Omega-3 (EPA/DHA) vs Telmisartan
A side-by-side research comparison of Omega-3 (EPA/DHA) and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Omega-3 (EPA/DHA) | Telmisartan |
|---|---|---|
| Full name | Omega-3 Fatty Acids (EPA + DHA) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement / FDA-approved (Rx fish oil) | FDA-approved drug |
| Mechanism | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | EPA: 302.45 Da, DHA: 328.49 Da | 514.62 Da |
| Half-life | ~48-72 hours (membrane incorporation) | ~24 hours |
| Bioavailability | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% | ~42-58% oral |
| Typical dose | 2-4g combined EPA+DHA | 20-80 mg per day |
| Frequency | Daily with meals | Once daily |
| Route | Oral (softgel, liquid) | Oral tablet |
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.